175 related articles for article (PubMed ID: 20041908)
21. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
Anglicheau D; Legendre C; Thervet E
Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
[TBL] [Abstract][Full Text] [Related]
22. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
23. Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients.
Hirano K; Naito T; Mino Y; Takayama T; Ozono S; Kawakami J
Clin Chim Acta; 2012 Dec; 414():120-4. PubMed ID: 22889968
[TBL] [Abstract][Full Text] [Related]
24. Optimization of initial tacrolimus dose using pharmacogenetic testing.
Thervet E; Loriot MA; Barbier S; Buchler M; Ficheux M; Choukroun G; Toupance O; Touchard G; Alberti C; Le Pogamp P; Moulin B; Le Meur Y; Heng AE; Subra JF; Beaune P; Legendre C
Clin Pharmacol Ther; 2010 Jun; 87(6):721-6. PubMed ID: 20393454
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
Lemaitre F; Bezian E; Goldwirt L; Fernandez C; Farinotti R; Varnous S; Urien S; Antignac M
Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
27. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.
Durand P; Debray D; Kolaci M; Bouligand J; Furlan V; Fabre M; Letierce A; Verstuyft C; Becquemont L
Pharmacogenomics; 2013 Jul; 14(9):1017-25. PubMed ID: 23837476
[TBL] [Abstract][Full Text] [Related]
29. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.
Wehland M; Bauer S; Brakemeier S; Burgwinkel P; Glander P; Kreutz R; Lorkowski C; Slowinski T; Neumayer HH; Budde K
Pharmacogenet Genomics; 2011 Apr; 21(4):179-84. PubMed ID: 20818295
[TBL] [Abstract][Full Text] [Related]
30. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
Min SI; Kim SY; Ahn SH; Min SK; Kim SH; Kim YS; Moon KC; Oh JM; Kim SJ; Ha J
Transplantation; 2010 Dec; 90(12):1394-400. PubMed ID: 21076384
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.
Larriba J; Imperiali N; Groppa R; Giordani C; Algranatti S; Redal MA
Transplant Proc; 2010; 42(1):257-9. PubMed ID: 20172323
[TBL] [Abstract][Full Text] [Related]
32. Everolimus in lung transplantation in Chile.
Parada MT; Alba A; Sepúlveda C
Transplant Proc; 2010; 42(1):328-30. PubMed ID: 20172343
[TBL] [Abstract][Full Text] [Related]
33. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
34. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
[TBL] [Abstract][Full Text] [Related]
35. The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.
Kniepeiss D; Wagner D; Wasler A; Tscheliessnigg KH; Renner W
Wien Klin Wochenschr; 2013 Jul; 125(13-14):393-5. PubMed ID: 23797529
[TBL] [Abstract][Full Text] [Related]
36. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
Ware N; MacPhee IA
Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.
Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Alvarez V;
Clin Chem Lab Med; 2011 May; 49(5):825-33. PubMed ID: 21480817
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.
Flahault A; Anglicheau D; Loriot MA; Thervet E; Pallet N
Pharmacogenomics; 2017 Jan; 18(2):165-173. PubMed ID: 27977332
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
